Risk stratification and treatment goals in pulmonary arterial hypertension
Стратификация риска и цели лечения при лёгочной артериальной гипертензии
2024-08-29
SCID: 54.1/3k8vf9pt
Discuss with AI
invasive haemodynamicspulmonary arterial hypertensionpulmonary vascular remodellingrisk stratificationtreatment goals
Figures from the paper
Abstract (AI)
Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters (World Health Organization functional class, 6-min walk distance and natriuretic peptides) that are included in all currently validated risk stratification tools. However, suffering from limitations mainly related to reduced specificity of PAH severity, these variables may not always be adequate in isolation for guiding individualised treatment decisions. Moreover, with effective combination treatment regimens and emerging PAH therapies, markers associated with pulmonary vascular remodelling are expected to become of increasing relevance in guiding the treatment of patients with PAH. While reaching a low mortality risk, assessed with a validated risk tool, remains an important treatment goal, preliminary data suggest that invasive haemodynamics and cardiac imaging may add incremental value in guiding treatment decisions.
Key Findings
1
Achieving low mortality risk remains a key treatment goal, while invasive hemodynamics and cardiac imaging may provide additional guidance for treatment decisions.
2
Markers of pulmonary vascular remodeling are expected to become increasingly relevant as combination therapies and new PAH treatments emerge.
3
Risk stratification is increasingly important for predicting outcomes and guiding treatment in pulmonary arterial hypertension.
4
These noninvasive variables have limited specificity for PAH severity and may be insufficient alone for individualized treatment decisions.
5
World Health Organization functional class, 6-minute walk distance, and natriuretic peptides are the most predictive noninvasive prognostic factors and are included in validated risk tools.
Research Object
Patients with pulmonary arterial hypertension (PAH)
Research Subject
Risk stratification, prognostic assessment, and treatment goals for guiding individualized PAH therapy
Publication Details
Publication Date
2024-08-29
Journal
Publisher
ISSN
Cited by
157
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai3
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2022
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model2017
Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension2019